Serplulimab for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Nov 2024: Trial started, NCT06727617
  2. 11 Dec 2024: Trial registered, NCT06727617

The trials

NCT06727617: Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors

State
Under way
Phase
Phase 2
People
134 planned
Started
19 Nov 2024
Primary completion
31 Dec 2025
Arms
Serplulimab plus chemoradiotherapy group
Results
None posted
  1. 19 Nov 2024: Trial started
  2. 11 Dec 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as HLX43 dose 1, HLX43 dose 2, Serplulimab and neoadjuvant therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.